Olendalizumab - Alexion Pharmaceuticals

Drug Profile

Olendalizumab - Alexion Pharmaceuticals

Alternative Names: ALXN-1007

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Anti-inflammatories; Antibodies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Antiphospholipid syndrome; Graft-versus-host disease
  • No development reported Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (IV, Infusion)
  • 14 Jun 2017 Alexion terminates a phase II trial due to slow patient enrolment in Antiphospholipid syndrome in Brazil, France, Italy, Spain, Japan, USA and United Kingdom (IV) (NCT02128269)
  • 15 Mar 2017 Alexion Pharmaceuticals terminates a phase-II trial in Graft-versus-host disease (Newly diagnosed) in France and USA (NCT02245412)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top